B. Metzler seel. Sohn & Co. Holding AG Purchases New Stake in Illumina, Inc. (NASDAQ:ILMN)

B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,441 shares of the life sciences company’s stock, valued at approximately $710,000.

Several other large investors also recently modified their holdings of the stock. Bank of New York Mellon Corp increased its position in Illumina by 7.2% in the second quarter. Bank of New York Mellon Corp now owns 3,039,538 shares of the life sciences company’s stock worth $317,267,000 after buying an additional 204,043 shares during the last quarter. Primecap Management Co. CA raised its stake in Illumina by 462.5% in the 2nd quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock valued at $253,514,000 after acquiring an additional 1,997,010 shares during the period. Millennium Management LLC raised its stake in Illumina by 305.0% in the 2nd quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock valued at $155,067,000 after acquiring an additional 1,118,747 shares during the period. Renaissance Technologies LLC increased its stake in shares of Illumina by 32.1% in the second quarter. Renaissance Technologies LLC now owns 1,000,318 shares of the life sciences company’s stock worth $104,413,000 after purchasing an additional 242,800 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Illumina in the second quarter valued at approximately $77,628,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on ILMN. Stephens lifted their price objective on shares of Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Citigroup increased their price objective on Illumina from $155.00 to $190.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Daiwa America upgraded Illumina to a “strong-buy” rating in a research report on Friday, August 16th. Argus upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a research report on Wednesday, August 28th. Finally, Leerink Partners upped their target price on shares of Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Illumina has a consensus rating of “Moderate Buy” and an average price target of $164.00.

Illumina Price Performance

Shares of Illumina stock opened at $140.14 on Friday. The firm has a market capitalization of $22.23 billion, a PE ratio of -14.07 and a beta of 1.13. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a 12 month low of $93.51 and a 12 month high of $156.66. The business’s 50-day moving average price is $140.61 and its 200-day moving average price is $124.84.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business’s quarterly revenue was down 3.5% on a year-over-year basis. During the same period last year, the business earned $0.33 earnings per share. Sell-side analysts forecast that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.